Efficacy and Safety of ICI-TKI Therapy for Metastatic Renal Cell Carcinoma

Six randomized controlled trials published between 2016 and 2025 were analyzed, pooling data from 3,637 patients. This systematic review and meta-analysis evaluates first-line immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for metastatic renal cell carcinoma. The work was authored by Yingliang Rao and uploaded to figshare in May 2026.

Use Cases

• Compare progression-free and overall survival outcomes based on IMDC risk stratification mentioned in the results
• Inform treatment strategy selection based on the synthesized efficacy and safety data from multiple RCTs
• Identify patient subgroups with the greatest clinical benefit based on the reported hazard ratios for different risk categories

Strengths

• Analysis is based on six randomized controlled trials, a standard for high-quality evidence
• Includes data from 3,637 patients across five trials for the primary analysis
• Reports specific hazard ratios and confidence intervals for progression-free and overall survival across IMDC risk subgroups

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The underlying data tables are not provided; the file contains the analysis document

Provenance

Source

Systematic review of PubMed, Embase, Cochrane Library, Web of Science, and conference proceedings.

Collection Method

Meta-analysis of randomized controlled trials using random-effects or fixed-effects models.

Time Range

Trials published from January 2016 to December 2025.

Freshness

Last updated 2026-05-15 09:57:41; freshness should be verified